Immunology-Immunopathology-Immunotherapy (I3) is a new research structure, directed by David KLATZMANN, devoted to translational immunology as a global aim, applied to the study of conditions such as auto-immune or infectious diseases and cancer. I3 has a strong and recognized scientific expertise in cellular immunology and most specifically in Treg studies, both in mice and human, and the I3 core structure and aims have a strong link with a medical campus. I3's core research mode will be classical though modern cellular immunology studies based on reductionist approaches towards better understanding of immunopathologies and rational development of immunotherapies. I3 also has the ambition to implement systems biology approaches within its translational immunology studies. Analyzing the overall organization of immune responses requires global approaches aimed not only at the individual components involved, but also at the complex interactions between them. I3 will thus introduce a truly global approach by studying the immune system as a tissue, bridging reductionist and systemic approaches, combining cytomic, genetic, transcriptomic and proteomic studies. I3 will be organized in four teams and four transversal activities (TA):

Team 1: Tolerance-Autoimmunity-Transplantation (TAT) (team leader Benoît SALOMON);
Team 2: Autoreactivity and Alloreactivity to Cancer (A2C) (team leader José COHEN);
Team 3: Immunotherapy and Viruses(IV) (team leader David KLATZMANN);
Team 4: Integrative Immunology: Differentiation, Diversity, Dynamics (I2D3)
(team leaders Véronique THOMAS-VASLIN and Adrien SIX).

TA1: Translational studies and ethics (managed by François LEMOINE);
TA2: Training and dissemination (managed by Eliane PIAGGIO and Bruno M. COLOMBO);
TA3: Technology and Scientific Intelligence, and environmental awareness (managed by Gilles MARODON);
TA4: Management & Valorization (managed by David KLATZMANN).

Many of the I3 researchers are medical doctors with hospital activities. In the preceding four years, the unit's experimental research led to seven clinical trials. With these records, I3 has the ambition to contribute to the advancement of medical knowledge and therapies in the field of immunology.

I3: Immunology-Immunopathology-Immunotherapy
UMR 7211 (UPMC/CNRS), U 959 (INSERM)
Bâtiment CERVI, CHU Pitié-Salpêtrière
83 boulevard de l'Hôpital
75651 Paris Cedex 13 (France)